- Home
- AIO vs KURA Comparison
AIO vs KURA Comparison
Compare AIO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- KURA
- Stock Information
- Founded
- AIO 2019
- KURA 2014
- Country
- AIO United States
- KURA United States
- Employees
- AIO N/A
- KURA N/A
- Industry
- AIO Finance/Investors Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIO Finance
- KURA Health Care
- Exchange
- AIO Nasdaq
- KURA Nasdaq
- Market Cap
- AIO 808.3M
- KURA 713.5M
- IPO Year
- AIO N/A
- KURA N/A
- Fundamental
- Price
- AIO $24.45
- KURA $8.19
- Analyst Decision
- AIO
- KURA Buy
- Analyst Count
- AIO 0
- KURA 14
- Target Price
- AIO N/A
- KURA $24.45
- AVG Volume (30 Days)
- AIO 141.5K
- KURA 2.0M
- Earning Date
- AIO 01-01-0001
- KURA 11-06-2025
- Dividend Yield
- AIO 9.05%
- KURA N/A
- EPS Growth
- AIO N/A
- KURA N/A
- EPS
- AIO N/A
- KURA N/A
- Revenue
- AIO N/A
- KURA $83,279,000.00
- Revenue This Year
- AIO N/A
- KURA $60.25
- Revenue Next Year
- AIO N/A
- KURA $155.10
- P/E Ratio
- AIO N/A
- KURA N/A
- Revenue Growth
- AIO N/A
- KURA N/A
- 52 Week Low
- AIO $15.09
- KURA $5.41
- 52 Week High
- AIO $20.25
- KURA $21.40
- Technical
- Relative Strength Index (RSI)
- AIO 53.59
- KURA 59.01
- Support Level
- AIO $24.03
- KURA $8.13
- Resistance Level
- AIO $24.85
- KURA $8.90
- Average True Range (ATR)
- AIO 0.37
- KURA 0.50
- MACD
- AIO 0.04
- KURA -0.01
- Stochastic Oscillator
- AIO 66.64
- KURA 51.65
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.